Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glimepiride
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Glimepiride is a second-generation sulfonylurea antidiabetic medication used primarily for the management of type 2 diabetes. It acts as an insulin secretagogue, stimulating pancreatic beta cells to release more insulin and increasing the activity of intracellular insulin receptors. Glimepiride is taken orally, typically once daily with breakfast or the first main meal, and is often prescribed alongside lifestyle modifications such as diet and exercise. It is not effective in patients with type 1 diabetes or diabetic ketoacidosis because it requires some endogenous insulin production to work. Common side effects include headache, nausea, dizziness, and hypoglycemia; serious adverse effects are rare but can include blood disorders. Glimepiride was patented in 1979 and approved for medical use in 1995; it is now widely available as a generic drug[1][2][5].
- Brand names
- Amaryl
- Other names
- 格列美脲
02
Targets
KCNJ11 (Atp-sensitive inward rectifier potassium channel 11)SUR2A (ATP-binding cassette sub-family C member 9)SUR2B (Sulfonylurea receptor 2B)KATP channel (ATP-sensitive potassium channel)SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on glimepiride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glimepiride.